.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,587,150

« Back to Dashboard

Summary for Patent: 5,587,150

Title: Photostable cosmetic screening composition containing a UV-A screening agent and an alkyl .beta., .beta.-diphenylacrylate or .alpha.-cyano-.beta. , .beta.-diphenylacrylate
Abstract:A photostable cosmetic screening composition and process for protection of the human epidermis against UV rays of wavelengths between 280 and 380 nm, the composition having, in a cosmetically acceptable vehicle containing at least one fatty phase, 1 to 5% by weight of a dibenzoylmethane derivative and at least 1% by weight of an alkyl .beta.-.beta.-diphenylacrylate or .alpha.-cyano-.beta.-.beta.-diphenylacrylate of formula (I), the mole ratio of the compound of formula (I) to the dibenzoylmethane derivative being not less than 0.8.
Inventor(s): Deflandre; Andre (Orry-la-Ville, FR), Dubois; Michel (Coulommiers, FR), Forestier; Serge (Claye-Souilly, FR), Richard; Herve (Paris, FR)
Assignee: L'Oreal (Paris, FR)
Application Number:08/461,842
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation;
Patent PDF download available with subscription

No matches for this query

Foreign Priority and PCT Information for Patent: 5,587,150

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France90 01761Feb 14, 1990

International Patent Family for Patent: 5,587,150

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina248083<disabled in preview>
Austria96654<disabled in preview>
Australia652742<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc